Patents Assigned to TargaGenix, Inc.
-
Publication number: 20250009658Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.Type: ApplicationFiled: July 16, 2024Publication date: January 9, 2025Applicants: TargaGenix, Inc., Research Foundation for State University New York, Northeastern UniversityInventors: James E. EGAN, Iwao OJIMA, Mansoor M. AMIJI, Galina Ivanovna BOTCHKINA
-
Patent number: 12186428Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.Type: GrantFiled: November 14, 2022Date of Patent: January 7, 2025Assignees: TargaGenix, Inc., The Research Foundation for the State University of New York, Northeastern UniversityInventors: James E. Egan, Mansoor M. Amiji, Iwao Ojima
-
Publication number: 20230082272Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.Type: ApplicationFiled: November 14, 2022Publication date: March 16, 2023Applicants: TargaGenix, Inc., The Research Foundation for the State University of New York, Northeastern UniversityInventors: James E. EGAN, Mansoor M. AMIJI, Iwao OJIMA
-
Patent number: 11497713Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.Type: GrantFiled: December 19, 2018Date of Patent: November 15, 2022Assignees: TargaGenix, Inc., The Research Foundation for The State University of New York, Northeastern UniversityInventors: James E. Egan, Mansoor Amiji, Iwao Ojima
-
Publication number: 20190183796Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.Type: ApplicationFiled: December 19, 2018Publication date: June 20, 2019Applicants: TargaGenix, Inc., The Research Foundation for The State University of New York, Northeastern UniversityInventors: James E. Egan, Mansoor Amiji, Iwao Ojima
-
Patent number: 10206875Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.Type: GrantFiled: June 7, 2017Date of Patent: February 19, 2019Assignees: TargaGenix, Inc., The Research Foundation for the State University New York, Northeastern UniversityInventors: James E. Egan, Iwao Ojima, Mansoor M. Amiji, Galina Ivanovna Botchkina
-
Publication number: 20180028442Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.Type: ApplicationFiled: June 7, 2017Publication date: February 1, 2018Applicants: TargaGenix, Inc., The Research Foundation for the State University New York, Northeastern UniversityInventors: James E. EGAN, Iwao OJIMA, Mansoor M. AMIJI, Galina Ivanovna BOTCHKINA
-
Patent number: RE50096Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.Type: GrantFiled: February 19, 2021Date of Patent: August 27, 2024Assignees: Targagenix, Inc., Northeastern UniversityInventors: James E. Egan, Iwao Ojima, Mansoor M. Amiji, Galina Ivanovna Botchkina